GPR50 Antibody

What is GPR50 and why is it significant in neuroscience research?

GPR50 (G protein-coupled receptor 50) is a member of the G-protein coupled receptor 1 family. It shares structural similarity with melatonin receptors but does not bind melatonin itself. Recent research has identified GPR50 as a novel mitophagy receptor essential for maintaining mitochondrial oxidative phosphorylation (OXPHOS) in developing neurons. This finding has elevated its significance in neuroscience, as proper mitochondrial function is critical for neuronal development and function. GPR50 has gained particular attention because mutations in this protein have been associated with neurodevelopmental disorders, including autism spectrum disorder (ASD) . Studies show that GPR50-deficient neurons display reduced dendritic complexity, shorter dendrites, and fewer dendritic branches, highlighting its crucial role in proper neural development .

What types of GPR50 antibodies are currently available for research applications?

Several types of GPR50 antibodies are available for research, each with specific characteristics and applications:

Mouse monoclonal antibodies target specific epitopes (Met1-Val617) within GPR50, while rabbit polyclonal antibodies are generated against either GPR50 fusion proteins or specific peptide sequences . The choice depends on the application, with monoclonals offering high specificity for particular epitopes and polyclonals providing broader epitope recognition across multiple techniques.

Which cell lines and tissue models are recommended for GPR50 antibody validation?

Based on validated research protocols, the following cellular and tissue models are recommended for GPR50 antibody applications:

Cell Lines:

• A172 human glioblastoma cells: Validated for immunofluorescence and flow cytometry

• HEK-293 cells: Effective for Western blot detection of GPR50

• HeLa cells: Suitable for both Western blot and immunoprecipitation applications

• SH-SY5Y neuroblastoma cells: Ideal for immunofluorescence and immunocytochemistry studies

Tissue Models:

• Mouse brain tissue, particularly hippocampus: Recommended for immunohistochemistry and immunofluorescence

• Primary neuronal cultures from mouse pups: Valuable for studying GPR50's role in neuronal development

When selecting a model system, consider the specific research question and the validated reactivity of your chosen antibody with human and/or mouse samples.

What are the recommended dilutions and conditions for different GPR50 antibody applications?

The optimal working dilutions for GPR50 antibodies vary by application type and specific antibody formulation:

Always perform a dilution series when using a GPR50 antibody in a new experimental system to determine the optimal working concentration for your specific conditions and samples .

How should I optimize immunofluorescence protocols for GPR50 detection in neural tissues?

Optimizing immunofluorescence for GPR50 detection in neural tissues requires careful attention to several key parameters:

Fixation:

• For cell lines: 4% paraformaldehyde for 10-15 minutes at room temperature

• For brain tissue: Perfusion fixation followed by post-fixation (4% PFA)

Antigen Retrieval:

• Recommended: TE buffer at pH 9.0 for heat-induced epitope retrieval

• Alternative: Citrate buffer at pH 6.0 if TE buffer yields suboptimal results

Permeabilization:

• For cultured cells: 0.1-0.3% Triton X-100 or saponin for intracellular staining

• For tissue sections: 0.3% Triton X-100 in PBS for 10-15 minutes

Blocking:

• 5-10% normal serum (from same species as secondary antibody)

• Add 1-2% BSA to reduce non-specific binding

• Block for at least 1 hour at room temperature

Primary Antibody:

• Dilute according to manufacturer's recommendation (typically 1:100-1:200)

• Incubate overnight at 4°C or for 3 hours at room temperature

Secondary Antibody:

• Choose appropriate conjugated secondary (e.g., NorthernLights 557 Anti-Mouse IgG)

• Include DAPI for nuclear counterstaining

Mounting:

• Use anti-fade mounting medium to preserve signal intensity

When working with mouse brain tissue, careful handling during sectioning and consistent processing across samples is essential for reliable results.

What controls should be included when performing Western blot analysis with GPR50 antibodies?

A comprehensive Western blot experiment with GPR50 antibodies should include the following controls:

Essential Controls:

• Positive Control: Include lysates from cells known to express GPR50 (HEK-293, HeLa, or A172 cells)

• Negative Control: Use lysates from GPR50 knockout/knockdown cells or tissues

• Loading Control: Probe for housekeeping proteins (β-actin, GAPDH, tubulin)

• Molecular Weight Marker: Verify the 67 kDa band for GPR50

• Secondary Antibody Control: Omit primary antibody to detect non-specific binding

Additional Validation Controls:

• Isotype Control: Use matched irrelevant antibody (e.g., MAB0031 for mouse monoclonals)

• Peptide Competition: Pre-absorb antibody with immunizing peptide to confirm specificity

• Multiple Antibodies: Test different antibodies targeting distinct GPR50 epitopes

Technical Controls:

• Gradient Loading: Run a concentration series to assess sensitivity and linearity

• Reducing vs. Non-reducing: Compare conditions if studying multimerization

These controls help verify antibody specificity, appropriate experimental conditions, and accurate identification of GPR50 protein bands, reducing the risk of false results and enabling meaningful interpretation of experimental outcomes.

How can GPR50 antibodies be used to study mitophagy in neuronal development?

GPR50 antibodies provide valuable tools for investigating its recently discovered function as a mitophagy receptor in neuronal development through several methodological approaches:

Co-localization Studies:

• Double immunofluorescence staining with GPR50 antibodies and mitochondrial markers

• Triple labeling with autophagic markers (LC3B, p62/SQSTM1) to visualize mitophagy events

• Quantify co-localization using computer-assisted image analysis

Functional Mitophagy Assays:

• Compare mitophagy rates in wild-type versus GPR50-deficient neurons

• Perform rescue experiments with wild-type GPR50 or mutant variants (T532A, Δ502-505)

• Track mitochondrial clearance under basal and stress-induced conditions

Developmental Analysis:

• Map GPR50 expression throughout neuronal development (DIV1-21)

• Correlate with dendritic complexity measurements

• Examine temporal relationships between mitophagy events and dendrite elaboration

Mutation Impact Studies:

• Compare neurons expressing wild-type GPR50 versus ASD-linked mutations

• Quantify differences in neuronal morphology and correlate with mitophagy defects

• Evaluate functional domains like the LIR motif to confirm direct mitophagy receptor mechanism

Research has demonstrated that neither ASD mutants (T532A, Δ502-505) nor mitophagy-related LIR mutants can rescue the developmental defects seen in GPR50-deficient neurons, supporting the critical role of GPR50-mediated mitophagy in proper neuronal development .

How do mutations in GPR50 affect neuronal development, and how can antibodies help study these effects?

Mutations in GPR50, particularly those associated with autism spectrum disorder (ASD) like T532A and Δ502-505, significantly impact neuronal development. GPR50 antibodies enable detailed analysis of these effects through several approaches:

Morphological Analysis:

• Immunostaining of primary neurons with GPR50 antibodies alongside dendritic markers (MAP2)

• Quantification of neuronal parameters: dendrite length, branching complexity, spine density

• Comparative analysis between wild-type, GPR50-deficient, and mutant-expressing neurons

Rescue Experiments:

• Transfect GPR50-deficient neurons with wild-type or mutant constructs

• Confirm expression using GPR50 antibodies

• Measure restoration of normal morphology and development

Research findings demonstrate:

• GPR50-deficient neurons show reduced dendritic complexity, shorter dendrites, and fewer branches

• Wild-type GPR50, when transfected, partially rescues these defects

• Neither ASD mutants (T532A, Δ502-505) nor mLIR mutants rescue dendritic development

Functional Analysis:

• Use GPR50 antibodies to track recruitment to damaged mitochondria

• Correlate mitochondrial function with GPR50 expression and localization

• Perform time-course studies of dendritic development with regular antibody staining

These antibody-based techniques provide critical insights into how GPR50 mutations disrupt normal neuronal development, potentially contributing to neurodevelopmental disorders like ASD .

What are the best approaches for using GPR50 antibodies in co-immunoprecipitation experiments?

Optimizing co-immunoprecipitation (Co-IP) experiments with GPR50 antibodies requires careful consideration of multiple factors:

Antibody Selection:

• Choose antibodies validated specifically for IP applications (e.g., 21514-1-AP)

• For rabbit polyclonal antibodies, typically use 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

Cell/Tissue Preparation:

• For cell lines (HeLa cells work well for GPR50 IP):

  • Harvest at 80-90% confluence

  • Lyse in mild, non-denaturing buffer (RIPA or NP-40 buffer)

• For brain tissue:

  • Rapidly dissect and process fresh tissue

  • Homogenize in IP-compatible buffer with protease inhibitors

Protocol Optimization:

• Pre-clear lysate with Protein A/G beads to reduce non-specific binding

• Incubate pre-cleared lysate with GPR50 antibody overnight at 4°C

• Perform 4-5 washes with decreasing detergent concentrations

• Elute with SDS sample buffer at lower temperature (70°C) to reduce aggregation

Essential Controls:

• Input control: 5-10% of pre-IP lysate

• IgG control: Isotype-matched irrelevant antibody

• Reverse Co-IP: Immunoprecipitate with antibodies against suspected interaction partners

• Western blot validation of pulled-down complexes

For studying GPR50's role in mitophagy, specifically examine interactions with autophagy machinery components and mitochondrial proteins in the immunoprecipitated samples .

Why might GPR50 antibody staining show different patterns in different neural cell types?

Differential GPR50 antibody staining patterns across neural cell types can result from both biological and technical factors:

Biological Variations:

• Cell type-specific transcriptional regulation of GPR50

• Different subcellular localization based on cellular function

• Post-translational modifications affecting epitope accessibility

• Varying protein interaction partners that may mask antibody binding sites

Technical Considerations:

• Fixation effects: Different cell types respond differently to fixation protocols

• Permeabilization sensitivity: Neural cell types have varying membrane compositions

• Antibody penetration: Myelinated regions may show reduced antibody accessibility

• Autofluorescence interference: Cell type-specific autofluorescence profiles

Methodological Approaches:

• Validate with multiple antibodies targeting different GPR50 epitopes

• Compare staining with mRNA expression data

• Use cell type-specific markers (NeuN, GFAP, Olig2) in co-staining experiments

• Optimize protocols specifically for each cell type

Understanding these factors is crucial for accurate interpretation of GPR50 staining patterns and for distinguishing true biological variations from technical artifacts. Notably, GPR50 has been detected in both neuronal cells (SH-SY5Y) and glial-derived cells (A172 glioblastoma), suggesting potential functional roles across neural cell types .

What factors might affect the apparent molecular weight of GPR50 in Western blot analysis?

Several factors can influence the apparent molecular weight of GPR50 in Western blot analysis, causing deviation from the calculated 67 kDa size:

Post-translational Modifications:

• Glycosylation: GPR50 is a membrane protein that may undergo N-linked and/or O-linked glycosylation

• Phosphorylation: Multiple phosphorylation sites can add approximately 0.5-1 kDa per phosphate group

• Ubiquitination: Single or poly-ubiquitination can significantly increase molecular weight

Sample Preparation Factors:

• Denaturation conditions: Incomplete denaturation may result in compact migration

• Reducing conditions: Insufficient reducing agent may allow disulfide bonds to persist

• Heating duration: Over-heating membrane proteins can cause aggregation

Gel System Variables:

• Acrylamide percentage: Lower percentage gels (8-10%) provide better resolution for proteins near GPR50's size

• Buffer system: Different systems affect migration patterns

• Running conditions: Voltage and duration impact protein migration

Technical Optimizations:

• Use gradient gels (4-15%) for better resolution

• Include deglycosylation controls (PNGase F treatment)

• Compare migration in different buffer systems

• Test different reducing agent concentrations

• Try varying heating temperatures (70°C vs. 95°C)

How should contradictory GPR50 antibody staining patterns across different studies be interpreted?

When facing contradictory GPR50 antibody staining patterns across studies, researchers should apply a systematic analytical framework:

Methodological Differences Assessment:

• Compare antibody characteristics:

Sample Variation Analysis:

• Species differences: Human vs. mouse GPR50 sequence variations affecting epitope recognition

• Tissue preparation: Perfusion-fixed vs. immersion-fixed tissues yield different results

• Developmental stage: Age-dependent expression patterns may explain contradictions

Biological Interpretation Frameworks:

• Cell type heterogeneity: Neuron subtype-specific expression patterns

• Subcellular localization dynamics: Activity-dependent translocation

• Mitophagy-associated redistribution: GPR50's role as a mitophagy receptor suggests dynamic localization

Resolution Through Systematic Comparison:

• Direct side-by-side testing of antibodies under identical conditions

• Correlation with mRNA expression data

• Epitope mapping to identify recognition sites

• Genetic validation using knockout/knockdown controls

By applying this structured analytical approach, researchers can better determine whether contradictions represent true biological complexity in GPR50 expression/function or methodological differences, leading to more accurate interpretation of results .

What are the most critical considerations when selecting GPR50 antibodies for neurodevelopmental research?

When selecting GPR50 antibodies for neurodevelopmental research, researchers should prioritize:

Research Question Alignment:

• Choose antibodies validated for your specific application (WB, IHC, IF, IP)

• Consider whether you need to detect specific domains or mutations

• Determine if you require detection of post-translational modifications

Validation Status:

• Select antibodies with validation in neural tissues/cells similar to your experimental system

• Check for knockout/knockdown validation data

• Review published literature using the specific antibody clone

Technical Specifications:

• Host species compatibility with your experimental design

• Monoclonal vs. polyclonal based on specificity requirements

• Species reactivity (human, mouse, or both)

Application-Specific Considerations:

• For developmental studies: Antibodies validated across developmental timepoints

• For mitophagy research: Antibodies that don't interfere with LIR motif recognition

• For mutant analysis: Antibodies that recognize both wild-type and mutant forms

Research findings confirm GPR50's critical role in neuronal development through its function as a mitophagy receptor. Therefore, antibodies that enable proper detection of this protein in neuronal contexts, particularly those that can differentiate between functional and mutant forms, are invaluable for advancing our understanding of neurodevelopmental disorders .

How might future research applications of GPR50 antibodies contribute to understanding neurodevelopmental disorders?

Future research applications of GPR50 antibodies hold significant promise for advancing our understanding of neurodevelopmental disorders through several avenues:

Patient-Derived Models:

• Immunoprofiling of GPR50 in iPSC-derived neurons from ASD patients

• Comparison of GPR50 localization and function between patient and control neurons

• Correlation of specific mutations with altered mitophagy and neuronal development

High-Resolution Imaging:

• Super-resolution microscopy to precisely map GPR50's mitochondrial association

• Live-cell imaging with compatible antibody formats to track dynamic changes

• Spatial transcriptomics combined with antibody staining for comprehensive analysis

Therapeutic Development:

• Screening compounds that modulate GPR50 function or expression

• Using antibodies to track restoration of proper GPR50 localization

• Assessing effects of potential therapies on neuronal development and mitophagy

Biomarker Potential:

• Evaluation of GPR50 as a potential biomarker for specific neurodevelopmental subtypes

• Correlating GPR50 variants with clinical phenotypes

• Development of diagnostic tools based on GPR50 status

Recent research has already demonstrated that GPR50 functions as a mitophagy receptor essential for neuronal development, with ASD-associated mutations disrupting this function. This foundation establishes GPR50 as a promising target for further investigation into the molecular mechanisms underlying neurodevelopmental disorders, with antibodies serving as crucial tools for advancing this research .